Theravance Inc $23.30

down -0.02


19/8/2014 04:00 PM  |  NASDAQ : THRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get THRX Trend Analysis - it has underperformed the S&P 500 by 55%

Partner Headlines

  1. Barron's Recap: Ready To Wear?

    Benzinga
  2. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

    Benzinga
  3. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On ...

    Benzinga
  4. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, Corporate ...

    Benzinga
  5. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga
  6. Benzinga's Top Downgrades

    Benzinga
  7. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies Considering ...

    Benzinga
  8. Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in ...

    Benzinga
  9. Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational ...

    Benzinga
  10. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  11. Morgan Stanley Expects Theravance to Continue to Underperform Following ...

    Benzinga
  12. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  13. Positive data for asthma drug

    IBD
  14. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  15. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, ...

    GuruFocus
  16. GlaxoSmithKline

    IBD
  17. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  18. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  19. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  20. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI ...

    Benzinga
  21. Theravance Reports Results from Phase 2B Study 0091 with TD-4208 for COPD, ...

    Benzinga
  22. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  23. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  24. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  25. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC ...

    Benzinga
  26. Theravance to Offer $250 Million Convertible Subordinated Notes Due 2023

    Benzinga
  27. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  28. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  29. Theravance Offers FDA Briefing Documents for Panel Meeting on VIBATIV(R)

    Benzinga
  30. Theravance Enters Agreement With Alfa Wassermann Worth Up To $53.5M

    Benzinga
  31. The Baupost Group's Favorite Stocks

    Benzinga
  32. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 Shares

    GuruFocus
  33. GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily ...

    Benzinga
  34. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  35. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60,000 Shares

    GuruFocus
  36. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  37. A Peek Into The Market Before The Trading Starts

    Benzinga
  38. GSK and Theravance Announce Regulatory Submissions for FF/VI in the US ...

    Benzinga
  39. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  40. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  41. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness
  42. Health Care Sector Wrap

    FoxBusiness
  43. Health Care Sector Wrap

    FoxBusiness
  44. GSK and Theravance Announce Positive Results From Four Pivotal Phase III ...

    Benzinga
  45. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  46. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  47. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  48. Afternoon Movers; Markets Moved Higher

    Benzinga
  49. Morning Market Losers

    Benzinga
  50. From Earlier: GSK and Theravance Announce Initial Outcomes From Pivotal ...

    Benzinga
Trading Center